

Beata Franczyk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9125472/publications.pdf>

Version: 2024-02-01

58
papers

1,409
citations

361296

20
h-index

395590

33
g-index

59
all docs

59
docs citations

59
times ranked

1950
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1702.	1.8	183
2	The Impact of CKD on Uremic Toxins and Gut Microbiota. <i>Toxins</i> , 2021, 13, 252.	1.5	114
3	The Effect of Diet on the Survival of Patients with Chronic Kidney Disease. <i>Nutrients</i> , 2017, 9, 495.	1.7	71
4	The Influence of Inflammation on Anemia in CKD Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 725.	1.8	68
5	Vegetarian Diet in Chronic Kidney Disease—A Friend or Foe. <i>Nutrients</i> , 2017, 9, 374.	1.7	63
6	Molecular mechanisms of statin intolerance. <i>Archives of Medical Science</i> , 2016, 3, 645-658.	0.4	58
7	The Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 601.	1.8	54
8	Serum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures. <i>International Urology and Nephrology</i> , 2020, 52, 2135-2143.	0.6	41
9	Pharmacogenomics of Hypertension Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4709.	1.8	40
10	Arterial Hypertension—Oxidative Stress and Inflammation. <i>Antioxidants</i> , 2022, 11, 172.	2.2	37
11	Acute Kidney Injury in COVID-19. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8081.	1.8	31
12	Heart function disturbances in chronic kidney disease — echocardiographic indices. <i>Archives of Medical Science</i> , 2014, 6, 1109-1116.	0.4	30
13	Oxidative Stress in ESRD Patients on Dialysis and the Risk of Cardiovascular Diseases. <i>Antioxidants</i> , 2020, 9, 1079.	2.2	28
14	Prevention of sudden cardiac death in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2012, 13, 162.	0.8	27
15	The Role of the Microbiome-Brain-Gut Axis in the Pathogenesis of Depressive Disorder. <i>Nutrients</i> , 2022, 14, 1921.	1.7	27
16	State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease. <i>Archives of Medical Science</i> , 2013, 6, 1019-1027.	0.4	25
17	Sudden cardiac death in CKD patients. <i>International Urology and Nephrology</i> , 2015, 47, 971-982.	0.6	25
18	Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study. <i>Lipids in Health and Disease</i> , 2016, 15, 22.	1.2	25

#	ARTICLE	IF	CITATIONS
19	Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients. <i>Nutrients</i> , 2018, 10, 709.	1.7	23
20	Is a High HDL-Cholesterol Level Always Beneficial?. <i>Biomedicines</i> , 2021, 9, 1083.	1.4	22
21	What Is the Role of Gut Microbiota in Obesity Prevalence? A Few Words about Gut Microbiota and Its Association with Obesity and Related Diseases. <i>Microorganisms</i> , 2022, 10, 52.	1.6	22
22	The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2017, 23, 2488-2495.	0.9	21
23	miRNA biomarkers in renal disease. <i>International Urology and Nephrology</i> , 2022, 54, 575-588.	0.6	18
24	Acute Coronary Syndromes in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2013, 11, 758-767.	0.8	18
25	Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. <i>International Urology and Nephrology</i> , 2017, 49, 155-164.	0.6	17
26	Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury. <i>Current Medicinal Chemistry</i> , 2021, 28, 1234-1250.	1.2	17
27	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	0.9	16
28	Oxidative Stress-Related Susceptibility to Aneurysm in Marfan's Syndrome. <i>Biomedicines</i> , 2021, 9, 1171.	1.4	16
29	Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 151.	1.8	15
30	Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients. <i>Nutrients</i> , 2019, 11, 2820.	1.7	14
31	Metabolomic Profile in Venous Thromboembolism (VTE). <i>Metabolites</i> , 2021, 11, 495.	1.3	14
32	Pathomechanisms of Immunological Disturbances in β -Thalassemia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9677.	1.8	14
33	Evaluation of Endothelial (dys)Function, Left Ventricular Structure and Function in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016, 14, 360-367.	0.8	14
34	Ageing, Age-Related Cardiovascular Risk and the Beneficial Role of Natural Components Intake. <i>International Journal of Molecular Sciences</i> , 2022, 23, 183.	1.8	14
35	Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2049-2056.	0.9	13
36	Diabetes and Cardiovascular Risk in Renal Transplant Patients. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3422.	1.8	13

#	ARTICLE	IF	CITATIONS
37	The Correlation between Lipid Metabolism Disorders and Prostate Cancer. <i>Current Medicinal Chemistry</i> , 2021, 28, 2048-2061.	1.2	13
38	Renal Cell Cancer and Obesity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3404.	1.8	13
39	The Role of Metabolic Factors in Renal Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7246.	1.8	12
40	Molecular Interactions of Arterial Hypertension in Its Target Organs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9669.	1.8	11
41	Mineralocorticoid Receptor Antagonistsâ€™ Use in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9995.	1.8	11
42	The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease. <i>Current Vascular Pharmacology</i> , 2016, 14, 260-265.	0.8	11
43	Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. <i>Current Vascular Pharmacology</i> , 2019, 17, 365-375.	0.8	10
44	Emerging Anti-Atherosclerotic Therapies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12109.	1.8	10
45	Pharmacogenetics of Drugs Used in the Treatment of Cancers. <i>Genes</i> , 2022, 13, 311.	1.0	10
46	Hypertension - Current Natural Strategies to Lower Blood Pressure. <i>Current Pharmaceutical Design</i> , 2017, 23, 2453-2461.	0.9	9
47	The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis. <i>International Urology and Nephrology</i> , 2017, 49, 1071-1077.	0.6	7
48	High-Sensitivity C-Reactive Protein Relationship with Metabolic Disorders and Cardiovascular Diseases Risk Factors. <i>Life</i> , 2021, 11, 742.	1.1	7
49	The Influence of Dietary Interventions on Chronic Kidney Diseaseâ€™ Mineral and Bone Disorder (CKD-MBD). <i>Nutrients</i> , 2021, 13, 2065.	1.7	6
50	Empagliflozinâ€™ A New Chance for Patients with Chronic Heart Failure. <i>Pharmaceutics</i> , 2022, 15, 47.	1.7	6
51	Are Nutraceuticals Beneficial in Chronic Kidney Disease?. <i>Pharmaceutics</i> , 2021, 13, 231.	2.0	5
52	Impact of Continuous Erythropoietin Receptor Activator on Selected Biomarkers of Cardiovascular Disease and Left Ventricle Structure and Function in Chronic Kidney Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-9.	1.9	4
53	Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?. <i>Current Pharmaceutical Design</i> , 2017, 23, 3024-3033.	0.9	4
54	Diabetes-induced Alterations in HDL Subfractions Distribution. <i>Current Pharmaceutical Design</i> , 2020, 26, 3341-3348.	0.9	4

#	ARTICLE	IF	CITATIONS
55	Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients. <i>Current Vascular Pharmacology</i> , 2017, 15, 123-134.	0.8	4
56	Biomarkers of Cardiovascular Risk in Haemodialysis Patients. <i>Current Pharmaceutical Design</i> , 2018, 23, 6086-6095.	0.9	2
57	Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1248.	1.8	1
58	Markers of increased cardiovascular risk in elderly patients with chronic kidney disease: A preliminary study. <i>Atherosclerosis</i> , 2015, 241, e184.	0.4	0